TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11606677

Group type: EXPERIMENTAL
Intervention: Neurobehavioural Rating Scale-Revised (NRS-R)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Glasgow Outcome Scale (GOS)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Disability Rating Scale (DRS)
Number of subjects: 210
Study: 9145846

Group type: EXPERIMENTAL
Intervention: Norfloxacin (400 mg single dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rufloxacin (400 mg single dose)
Number of subjects: 0
Study: 7962435

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX) at approximately 3.6 mM in Earle's medium
Number of subjects: 0

Group type: COMPARATOR
Intervention: PTX-free Earle's medium (Control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX)
Number of subjects: 0
Study: 3595697

Group type: EXPERIMENTAL
Intervention: Diclofenac (preoperative administration)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Diclofenac (postoperative administration)
Number of subjects: 95
Study: 30355334

Group type: EXPERIMENTAL
Intervention: Perpendicular technique
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Parallel technique
Number of subjects: 12
Study: 27566586

Group type: EXPERIMENTAL
Intervention: Endostar antiangiogenic therapy combined with NP neoadjuvant chemotherapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: NP neoadjuvant chemotherapy alone
Number of subjects: 30
Study: 25070091

Group type: EXPERIMENTAL
Intervention: Metoprolol with PA
Number of subjects: 56

Group type: COMPARATOR
Intervention: PA redosing
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: PA administration
Number of subjects: 56
Study: 23583327

Group type: EXPERIMENTAL
Intervention: RECOS (individualized therapy)
Number of subjects: 138

Group type: COMPARATOR
Intervention: CRT (general cognitive remediation therapy)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: RECOS
Number of subjects: 138

Group type: COMPARATOR
Intervention: CRT
Number of subjects: 138

Group type: COMPARATOR
Intervention: RECOS and CRT
Number of subjects: 138
Study: 20153214

Group type: EXPERIMENTAL
Intervention: Segmentectomy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Lobectomy
Number of subjects: 80
Study: 18695455

Group type: EXPERIMENTAL
Intervention: web-based multimedia health promotion program
Number of subjects: 309

Group type: COMPARATOR
Intervention: wait-list control condition
Number of subjects: 309
Study: 16873785

Group type: EXPERIMENTAL
Intervention: Insulin glulisine (immediately premeal)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Insulin glulisine (15 min postmeal)
Number of subjects: 21

Group type: COMPARATOR
Intervention: RHI (30 min premeal)
Number of subjects: 21

Group type: COMPARATOR
Intervention: RHI (immediately premeal)
Number of subjects: 21
Study: 14655784

Group type: EXPERIMENTAL
Intervention: Clobetasol foam 0.05%
Number of subjects: 32

Group type: COMPARATOR
Intervention: Clobetasol cream 0.05% and solution 0.05%
Number of subjects: 32
Study: 10654330

Group type: EXPERIMENTAL
Intervention: Desmopressin (Adiuretin-SD) (n = 32)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Sodium diclofenac (n = 30)
Number of subjects: 62
Study: 9289710

Group type: EXPERIMENTAL
Intervention: Patients with AML, CGL-BC, and CLL
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Patients with CGL and CGL-BC
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Patients with CLL
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Patients with AML, CGL-BC, and CGL
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (12 healthy volunteers)
Number of subjects: 45
Study: 1792929

Group type: EXPERIMENTAL
Intervention: Amineptine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Minaprine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6339963

Group type: EXPERIMENTAL
Intervention: UV-A phototherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30696423

Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Moderate-intensity continuous training (MICT)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 36
Study: 30544877

Group type: EXPERIMENTAL
Intervention: Randomized Watermarking Filtering Scheme (RWFS)
Number of subjects: 0
Study: 26324844

Group type: EXPERIMENTAL
Intervention: 6 minute walk distance (6MWD) in the French cohort
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: 6 minute walk distance (6MWD) in the FDA cohort
Number of subjects: 415

Group type: COMPARATOR
Intervention: Changes in 6 minute walk distance (6MWD) during follow-up in treated patients
Number of subjects: 415
Study: 27128607

Group type: EXPERIMENTAL
Intervention: Mericitabine 1,500 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Mericitabine 9,000 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg (positive control)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 22187234

Group type: EXPERIMENTAL
Intervention: Combination therapy (200 mg celecoxib and 20 mg doxycycline, both twice daily)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Celecoxib (200 mg twice daily) only
Number of subjects: 75

Group type: COMPARATOR
Intervention: Non-therapy control
Number of subjects: 75
Study: 21094838

Group type: EXPERIMENTAL
Intervention: High-dose antithymocyte globulin (ATG) therapy plus shortened standard therapy (group 1)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard therapy (group 2)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: High-dose ATG therapy (group 1)
Number of subjects: 30
Study: 17426325

Group type: EXPERIMENTAL
Intervention: MK-0557 (1 mg/d)
Number of subjects: 502

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 502
Study: 15785225

Group type: EXPERIMENTAL
Intervention: Videoconferencing
Number of subjects: 400

Group type: COMPARATOR
Intervention: In-person interviews
Number of subjects: 400
Study: 12125299

Group type: EXPERIMENTAL
Intervention: Intensive Short‐term Dynamic Psychotherapy (ISTDP)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: ISTDP
Number of subjects: 89
Study: 10633764

Group type: EXPERIMENTAL
Intervention: CapSure (Re/Stor) continence shield
Number of subjects: 0
Study: 7796643

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA) 10 mg twice daily for three months
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA) 10 mg twice daily and cyclopentylethinyl estriol (CEE3) 5 mg once a month for three months
Number of subjects: 30
Study: 2127789

Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b treatment (3 million units, three times weekly, subcutaneously for 36 weeks)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b treatment
Number of subjects: 33
Study: 369644

Group type: EXPERIMENTAL
Intervention: Internal fixation (von Bahr screws)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Primary prosthetic replacement (Christiansen endoprosthesis)
Number of subjects: 104
Study: 30660638

Group type: EXPERIMENTAL
Intervention: Gamma tocopherol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 28432265

Group type: EXPERIMENTAL
Intervention: Actovegin (2000 mg/d for ≤20 intravenous infusions followed by 1200 mg/d orally)
Number of subjects: 503

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 503
Study: 25910427

Group type: EXPERIMENTAL
Intervention: C2 nerve field stimulation (minimal .1 mA, subthreshold, suprathreshold)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: C2 nerve field stimulation
Number of subjects: 40
Study: 23993734

Group type: EXPERIMENTAL
Intervention: Annual chest radiograph for 3 or 4 years
Number of subjects: 154900
Study: 22138934

Group type: EXPERIMENTAL
Intervention: Telemedicine encounter with IBD specialist remotely located
Number of subjects: 34

Group type: COMPARATOR
Intervention: Standard encounter
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Telemedicine encounter
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Telemedicine sessions
Number of subjects: 34
Study: 19593411

Group type: EXPERIMENTAL
Intervention: Adjunctive use of denicotinized cigarettes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nicotine replacement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bupropion
Number of subjects: 0
Study: 16844340

Group type: EXPERIMENTAL
Intervention: Neuropsychological services
Number of subjects: 517

Group type: EXPERIMENTAL
Intervention: Referral for diagnostic purposes
Number of subjects: 517

Group type: EXPERIMENTAL
Intervention: Barriers to referral
Number of subjects: 517

Group type: EXPERIMENTAL
Intervention: Primary care physicians
Number of subjects: 517
Study: 12780901

Group type: EXPERIMENTAL
Intervention: SCL/RBL (simultaneous sclerotherapy and rubber band ligation)
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: SCL (sclerotherapy)
Number of subjects: 255

Group type: COMPARATOR
Intervention: RBL (rubber band ligation)
Number of subjects: 255
Study: 11028571

Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing (20 μg/day) intrauterine system (LNG-20)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Intrauterine devices ≤ 250 mm3
Number of subjects: 5

Group type: COMPARATOR
Intervention: Intrauterine devices > 250 mm3
Number of subjects: 5

Group type: COMPARATOR
Intervention: Norplant-2
Number of subjects: 5
Study: 9198052

Group type: EXPERIMENTAL
Intervention: Intradermal administration of hepatitis B recombinant DNA yeast vaccine (80 micrograms)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intramuscular administration of hepatitis B recombinant DNA yeast vaccine (80 micrograms)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Cost of intradermal schedule
Number of subjects: 50
Study: 1376843

Group type: EXPERIMENTAL
Intervention: Isradipine 1.25 mg
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Isradipine 2.5 mg
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Isradipine 5 mg
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Isradipine (all groups)
Number of subjects: 27
Study: 3884404

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Conventional insulin treatment (CIT)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Comparison of CIT and CSII
Number of subjects: 10
Study: 30709385

Group type: EXPERIMENTAL
Intervention: 20-day Lenten-themed physical activity intervention (Savior's Sandals)
Number of subjects: 187

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 187
Study: 29177475

Group type: EXPERIMENTAL
Intervention: PVI plus ablation of low-voltage areas (LVAs)
Number of subjects: 124

Group type: COMPARATOR
Intervention: PVI with or without linear ablation (control group)
Number of subjects: 124
Study: 26457895

Group type: EXPERIMENTAL
Intervention: Early substitution group (ROTEM FIBTEM trigger <13 mm)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional group (ROTEM FIBTEM trigger <8 mm)
Number of subjects: 0
Study: 25498770

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 22310510

Group type: EXPERIMENTAL
Intervention: Hypoxic resistance exercise (HR)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Normoxic resistance exercise (NR)
Number of subjects: 8
Study: 19614793

Group type: EXPERIMENTAL
Intervention: Intensive intervention to reduce hemoglobin A(1c)
Number of subjects: 58
Study: 17889694

Group type: EXPERIMENTAL
Intervention: Water-cooled
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Air-cooled
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: No coolant
Number of subjects: 37
Study: 15191590

Group type: EXPERIMENTAL
Intervention: Enamel matrix proteins (EMD)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Guided tissue regeneration (GTR)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Combination of EMD and GTR
Number of subjects: 42

Group type: COMPARATOR
Intervention: Open flap debridement (OFD)
Number of subjects: 42
Study: 11755800

Group type: EXPERIMENTAL
Intervention: Early Intervention Program (EIP) with intense home visitation by public health nurses (PHNs)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Early Intervention Program (EIP)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Traditional Public Health Nursing care (TPHN)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Both EIP and TPHN
Number of subjects: 102
Study: 9848540

Group type: EXPERIMENTAL
Intervention: Metronidazole 250 mg plus Amoxicillin 500 mg, 3 times/day for a week
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Metronidazole plus Amoxicillin (M+A)
Number of subjects: 46
Study: 8024227

Group type: EXPERIMENTAL
Intervention: Calcium nadroparin (fixed dose: daily subcutaneous injection of 0.6 ml, i.e. 6150 anti‐Xa IU, n = 38)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Calcium nadroparin (weight-adjusted dose: 31.5 anti‐Xa IU/kg, n = 40)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Naproxen (500 mg as a single daily dose, n = 39)
Number of subjects: 117
Study: 2689915

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 1095134

Group type: EXPERIMENTAL
Intervention: Monofluorophosphate (25 mg fluoride per day)
Number of subjects: 460

Group type: COMPARATOR
Intervention: Control group (no fluoride treatment)
Number of subjects: 460
Study: 31153674

Group type: EXPERIMENTAL
Intervention: Chronotype-adjusted diet
Number of subjects: 209

Group type: COMPARATOR
Intervention: Typical hypocaloric dietary treatment
Number of subjects: 209
Study: 31814707

Group type: EXPERIMENTAL
Intervention: AZD7594 (1600 µg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: AZD7594
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 28407543

Group type: EXPERIMENTAL
Intervention: Smoked cannabis (6.9% THC, ∼54mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vaporized cannabis (6.9% THC, ∼54mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral cannabis (6.9% THC, ∼54mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (0.001% Δ9‐tetrahydrocannabinol [THC])
Number of subjects: 0
Study: 24486815

Group type: EXPERIMENTAL
Intervention: MRI while awake with age-adjusted routines (booklet, story book, model of MRI scanner, DVD film)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: MRI while awake with age-adjusted routines
Number of subjects: 69

Group type: COMPARATOR
Intervention: MRI under anesthesia
Number of subjects: 69

Group type: COMPARATOR
Intervention: MRI while awake
Number of subjects: 69
Study: 23247700

Group type: EXPERIMENTAL
Intervention: Chronic exercise (12-week supervised exercise program)
Number of subjects: 22
Study: 21689343

Group type: EXPERIMENTAL
Intervention: Patent blue V dye injection
Number of subjects: 68

Group type: COMPARATOR
Intervention: No patent blue V dye injection
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Both groups after application of Carnoy's solution
Number of subjects: 68
Study: 17676535

Group type: EXPERIMENTAL
Intervention: Paging system intervention for 7 weeks
Number of subjects: 4

Group type: COMPARATOR
Intervention: Baseline measurement (no pager)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Post-intervention monitoring (5 weeks after returning pagers)
Number of subjects: 4
Study: 16174897

Group type: EXPERIMENTAL
Intervention: Epsilon-aminocaproic acid (EACA) 5 g infused during 1 hour, then 1 g/hour for 23 hours
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (untreated patients)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Epsilon-aminocaproic acid (EACA)
Number of subjects: 14
Study: 11928795

Group type: EXPERIMENTAL
Intervention: Limb-sparing surgery with adjuvant radiation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Radiation therapy (external beam and brachytherapy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (not specified)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjuvant doxorubicin-based chemotherapy
Number of subjects: 0
Study: 9788526

Group type: EXPERIMENTAL
Intervention: Alprazolam (0, 1, 2 mg)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: d‐amphetamine (0, 12.5, 25 mg)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Codeine (0, 60, 120 mg)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Marijuana (0, 3.58% THC)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Drug Recognition Examiners (DREs) decisions
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Drug class decisions by DREs
Number of subjects: 48
Study: 7697134

Group type: EXPERIMENTAL
Intervention: DMSA (10 mg/kg, oral)
Number of subjects: 34

Group type: COMPARATOR
Intervention: EDTA (1 g, intravenous)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: DMSA after EDTA
Number of subjects: 34
Study: 2487304

Group type: EXPERIMENTAL
Intervention: Oral nitrofurantoin (100 mg t.i.d.) for five days
Number of subjects: 103

Group type: COMPARATOR
Intervention: Oral ampicillin (500 mg t.i.d.) for five days
Number of subjects: 103
Study: 20124

Group type: EXPERIMENTAL
Intervention: Mental arithmetic (5-min period)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Beta1-adrenoceptor selective blocker (metoprolol)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-selective blockers (e.g., propranolol)
Number of subjects: 0
Study: 31308592

Group type: EXPERIMENTAL
Intervention: Traditional BPB technique with 0.2 mL/kg BW of bupivacaine 0.5%
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Perpendicular BPB technique with 0.2 mL/kg BW of bupivacaine 0.5%
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Axillary BPB technique with 0.2 mL/kg BW of bupivacaine 0.5%
Number of subjects: 24

Group type: COMPARATOR
Intervention: Other surgical procedures (control group)
Number of subjects: 24
Study: 29275577

Group type: EXPERIMENTAL
Intervention: Sevoflurane/remifentanil maintenance regimen (group SR, n=50)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sevoflurane maintenance regimen (group S, n=50)
Number of subjects: 100
Study: 25173085

Group type: EXPERIMENTAL
Intervention: IMRT with dose constraints on the brachial plexus (BP) (maximum dose limit of ≤66 Gy)
Number of subjects: 30

Group type: COMPARATOR
Intervention: IMRT without restrictions for the BP
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: IMRT with dose constraints on the BP
Number of subjects: 30
Study: 23885792

Group type: EXPERIMENTAL
Intervention: Azilsartan (20-40 mg once daily)
Number of subjects: 548

Group type: COMPARATOR
Intervention: Candesartan (8-12 mg once daily)
Number of subjects: 548
Study: 21505785

Group type: COMPARATOR
Intervention: GPIbα C mutated allele in smokers
Number of subjects: 114

Group type: COMPARATOR
Intervention: PAR‐1A/T SNP and other SNPs tested
Number of subjects: 114

Group type: COMPARATOR
Intervention: GPIb‐α (5C/T) prevalence in smokers
Number of subjects: 114
Study: 18248979

Group type: EXPERIMENTAL
Intervention: Radiotherapy plus BCNU and DBD (n=94)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Radiotherapy alone (n=99)
Number of subjects: 193
Study: 16835585

Group type: EXPERIMENTAL
Intervention: Exemestane
Number of subjects: 60

Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 60
Study: 15356496

Group type: EXPERIMENTAL
Intervention: Fluoridated elastomers
Number of subjects: 30

Group type: COMPARATOR
Intervention: Nonfluoridated elastomers
Number of subjects: 30
Study: 11782868

Group type: EXPERIMENTAL
Intervention: Regular cow milk protein-based formula with added cholesterol (RF+cholesterol) 3.44 mmol cholesterol/L (133 mg cholesterol/L)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Regular cow milk protein-based formula (RF)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Breast-fed (BF)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Regular cow milk protein-based formula with added cholesterol (RF+cholesterol)
Number of subjects: 81
Study: 9667247

Group type: EXPERIMENTAL
Intervention: CHVP + IFNalpha
Number of subjects: 268

Group type: COMPARATOR
Intervention: CHVP alone
Number of subjects: 268
Study: 7700540

Group type: EXPERIMENTAL
Intervention: Lacidipine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 0
Study: 2748223

Group type: EXPERIMENTAL
Intervention: Active drug (salbutamol)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study: 341407

Group type: EXPERIMENTAL
Intervention: Clenbuterol (40 microgram)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Salbutamol (4 mg)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 31471767

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diabetes support and education program (DSE)
Number of subjects: 0
Study: 29292066

Group type: EXPERIMENTAL
Intervention: 200 ml of 5.0 ppm F milk once per day
Number of subjects: 25

Group type: COMPARATOR
Intervention: 100 ml of 5.0 ppm F twice per day
Number of subjects: 25

Group type: COMPARATOR
Intervention: 200 ml of 5.0 ppm F once every other day
Number of subjects: 25

Group type: COMPARATOR
Intervention: All groups (once per day, twice per day, once every other day)
Number of subjects: 25
Study: 26864002

Group type: EXPERIMENTAL
Intervention: Intrathecal anaesthesia with 40 mg intrathecal hyperbaric prilocaine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Peripheral nerve blockade with 25 ml mepivacaine 2%
Number of subjects: 100
Study: 25478791

Group type: EXPERIMENTAL
Intervention: 12-week Internet intervention providing tailored physical activity counseling
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard follow-up by school nurses (Control)
Number of subjects: 120
Study: 22506889

Group type: EXPERIMENTAL
Intervention: Shared reading program with print references (2 or 4 times per week for 30 weeks)
Number of subjects: 550

Group type: COMPARATOR
Intervention: Typical book reading style (comparison classrooms)
Number of subjects: 550
Study: 20169950

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.4 mg x kg(‐1)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.5 mg x kg(‐1)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg x kg(‐1)
Number of subjects: 30